Bionomics Limited (BNO.AX)
| Previous close | 0.2000 |
| Open | 0.2000 |
| Bid | 0.1850 x 2640300 |
| Ask | 0.1900 x 16362900 |
| Day's range | 0.1850 - 0.2000 |
| 52-week range | 0.0386 - 0.4850 |
| Volume | 768,797 |
| Avg. volume | 2,172,008 |
| Market cap | 187.427M |
| Beta (5Y monthly) | 2.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0010 |
| Earnings date | 16 Aug 2016 - 20 Aug 2016 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.63 |
- PR Newswire
Bionomics Successfully Completes A$22.9 million Equity Raise
Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics) has completed its 1 for 6 pro rata non–renounceable entitlement offer that was announced on 8 March 2021 (Entitlement Offer) and concurrent placement that was announced on 17 March 2021 (Concurrent Placement) which collectively raised approximately A$22.9 million.
- Simply Wall St.
Did You Participate In Any Of Bionomics' (ASX:BNO) Incredible 680% Return?
Bionomics Limited ( ASX:BNO ) shareholders might be concerned after seeing the share price drop 15% in the last week...
- PR Newswire
Positive BNC210 7-Day Dosing Pharmacokinetic Study Exceeds Blood Exposure Projected for Phase 2b PTSD Trial
Bionomics Limited (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5), a global, clinical stage biopharmaceutical company, today announced positive pharmacokinetic (PK) results from a 7-day dosing study in healthy volunteers using the newly developed solid dose oral tablet formulation of BNC210. BNC210 is a novel, negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor in development for the treatment of anxiety and stressor-related disorders, and in November 2019 was granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of Post-Traumatic Stress Disorder (PTSD).
